Swedish Orphan Biovitrum returns ITP asset rights to Symphogen
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum has returned full development rights to its immune thrombocytopenic purpura (ITP) treatment candidate to co-developer Symphogen as it prioritises its late-stage development pipeline.